News | 15 March 2023
Philips and Gibraltar Health Authority announce 16-year strategic partnership
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
A funding to expand operations and provide better patient care
Proposed combination enhances Pfizer’s position as a leading company in oncology
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
ALPLA is expanding its presence in the global market for pharmaceutical packaging by establishing a joint venture with Inden Pharma
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Marksans' OTC Famotidine Tablets USP are acid reducers
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
The agreement is for USFDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
Plantasens Pro LM is 100% natural, readily biodegradable, COSMOS and Natrue certified
The business serves the healthcare and laboratory sectors on the west coast of the United States.
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Ashland’s pharmaceutical business is well known for acetylenics, cellulosics, and film coatings
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
Natural Capsules Limited's shareholding will be reduced to 89.99%
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Subscribe To Our Newsletter & Stay Updated
